CERE vs. CNX, HCC, ARCH, HNRG, ALNY, TEVA, GMAB, RPRX, BMRN, and BGNE
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include CNX Resources (CNX), Warrior Met Coal (HCC), Arch Resources (ARCH), Hallador Energy (HNRG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE).
Cerevel Therapeutics (NASDAQ:CERE) and CNX Resources (NYSE:CNX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
CNX Resources has a net margin of 40.44% compared to Cerevel Therapeutics' net margin of 0.00%. CNX Resources' return on equity of 7.68% beat Cerevel Therapeutics' return on equity.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of CNX Resources shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by insiders. Comparatively, 3.1% of CNX Resources shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cerevel Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, CNX Resources has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
In the previous week, Cerevel Therapeutics had 4 more articles in the media than CNX Resources. MarketBeat recorded 9 mentions for Cerevel Therapeutics and 5 mentions for CNX Resources. CNX Resources' average media sentiment score of 0.95 beat Cerevel Therapeutics' score of 0.52 indicating that CNX Resources is being referred to more favorably in the news media.
Cerevel Therapeutics presently has a consensus target price of $42.67, indicating a potential upside of 6.61%. CNX Resources has a consensus target price of $25.00, indicating a potential downside of 1.50%. Given Cerevel Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cerevel Therapeutics is more favorable than CNX Resources.
CNX Resources has higher revenue and earnings than Cerevel Therapeutics.
CNX Resources received 661 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 70.59% of users gave CNX Resources an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
Summary
CNX Resources beats Cerevel Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cerevel Therapeutics Competitors List
Related Companies and Tools
